Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031 (NASDAQ:LTRN)
· seekingalpha.com
Lantern Pharma (LTRN) Q2 2026 earnings call recap: Open Medicine AI spinoff, LP-300/LP-184 trial updates, cash & financing risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...